Tibet Aim Pharm Inc

Chart & Performance

D1W1MN

P/E

71.93

P/S

5.07

EPS

0.25

Div Yield, %

0.16%

Shrs. gr., 5y

-0.64%

Rev. gr., 5y

3.34%

Revenues

652m

-2.27%

Net income

46m

+198.50%

CFO

112m

-33.14%

Dividend

May 31, 20240.03 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Tibet AIM Pharm. Inc. engages in the research and development of medical products in China. The company's products include Miglitol tablets for diabetes; Gualoupi injection for coronary disease; Oxytocin injection for gynecology and obstetrics; NalMefene injection for various acute poisoning, such as alcohol, organic phosphor, CO, sedative-hypnotic, opioid substance, serious infection, shock, fainting, and brain; Carbetocin injections; and Hongjin Xiaojie tablets and Aceclofenac Enteric-Coated tablets, as well as for the treatment of antibiotic, antiallergic, and digestive system. Tibet AIM Pharm. Inc. was founded in 2003 and is headquartered in Beijing, China.

URL

http://www.emyy.cn/

IPO date

Dec 09, 2016

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT